Tumor cells are required to undergo metabolic reprogramming for rapid development and
progression, and one of the metabolic characteristics of cancer cells is the excessive …

The identification of colorectal cancer (CRC) molecular targets is needed for the
development of drugs that improve patient survival. We investigated the functional role of …

Background: Phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole
succinocarboxamide synthetase (PAICS), an enzyme required for de novo purine …

Phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole
succinocarboxamide synthetase (PAICS), an essential enzyme involved in de novo purine …

Cancer cells exhibit altered metabolism including aerobic glycolysis that channels several
glycolytic intermediates into de novo purine biosynthetic pathway. We discovered increased …

Acute myeloid leukemia (AML) is a devastating disease, and clinical outcomes are still far
from satisfactory. Here, to identify novel targets for AML therapy, we performed a genome …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with an extremely poor
prognosis. There is an urgent need to identify new therapeutic targets and also understand …

Background Nucleotide metabolism is a critical pathway that generates purine and
pyrimidine molecules for DNA replication, RNA synthesis, and cellular bioenergetics …

Genomic and transcriptome sequencing of bladder cancer (BLCA) has identified multiple
molecular alterations during cancer progression. Many of these identified genetic and …

Unrestricted cell proliferation is a hallmark of cancer. Purines are basic components of
nucleotides in cell proliferation, thus impaired purine metabolism is associated with the …